Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 8/20 | 0.73 |
| ▸ | PTPRC | P08575 | 2/20 | 0.62 |
| ▸ | CSNK2A2 | P19784 | 6/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 6/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 6/20 | 0.54 |
| ▸ | CSNK2A3 | Q8NEV1 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31436146 | 1.00 | TTR (0.73) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5034849 | 0.86 | TTR (0.70) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL26187220 | 0.85 | TTR (1.00) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL31436145 | 0.84 | TTR (0.88) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL598301 | 0.84 | TTR (0.88) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL71021 | 0.84 | TTR (0.88) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL5073503 | 0.82 | MEN1 (0.71) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL599578 | 0.80 | TTR (0.81) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9815671 | 0.80 | TTR (0.55) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL9815749 | 0.80 | TTR (0.55) | TTRPTPRCCSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240243319-A1 | AQUEOUS ELECTROLYTE, SALTS USED THEREIN, AND REDOX FLOW BATTERY USING SAID AQUEOUS ELECTROLYTE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240243319-A1 | AQUEOUS ELECTROLYTE, SALTS USED THEREIN, AND REDOX FLOW BATTERY USING SAID AQUEOUS ELECTROLYTE | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-7504495-B2 | Quencher compositions comprising anthraquinone moieties | EXIQON A/S (DK) | 2009-03-17 | — | — | US | disclosed |
| US-7504495-B2 | Quencher compositions comprising anthraquinone moieties | EXIQON A/S (DK) | 2009-03-17 | — | — | US | disclosed |
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | QIAGEN GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| US-5484935-A | Pharmaceutical compounds | LILLY INDUSTRIES LIMITED (GB) | 1996-01-16 | — | — | US | disclosed |
| US-5430067-A | Dihydroanthraquinonecarboxylic acids | ELI LILLY AND COMPANY (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0638540-A1 | Pharmaceutical anthracene-2-carboxylic acid derivatives | LILLY INDUSTRIES LIMITED (GB) | 1995-02-15 | — | — | EP | disclosed |
| EP-0638562-A1 | Anthraquinone derivatives useful in the treatment of cancer and osteoartritis | LILLY INDUSTRIES LIMITED (GB) | 1995-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227254-A1 | Quencher compositions comprising anthraquinone moieties | ANXA5, SUN2, ANXA3 | TTR 3373/4885PTPRC 3481/4885CSNK2A2 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.